DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,244 filers reported holding DANAHER CORPORATION in Q2 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $599,139 | -0.9% | 2,398 | -1.0% | 0.04% | -2.2% |
Q1 2024 | $604,574 | +7.7% | 2,421 | -0.2% | 0.05% | 0.0% |
Q4 2023 | $561,229 | -22.2% | 2,426 | -16.6% | 0.05% | -28.1% |
Q3 2023 | $721,723 | -8.1% | 2,909 | -11.1% | 0.06% | -4.5% |
Q2 2023 | $785,520 | -86.1% | 3,273 | -85.4% | 0.07% | -86.7% |
Q1 2023 | $5,641,159 | -0.5% | 22,382 | +4.7% | 0.50% | -3.3% |
Q4 2022 | $5,672,032 | -8.6% | 21,370 | -11.1% | 0.52% | -16.0% |
Q3 2022 | $6,209,000 | +104.5% | 24,040 | +100.8% | 0.62% | +119.9% |
Q2 2022 | $3,036,000 | -60.8% | 11,973 | -54.7% | 0.28% | -57.5% |
Q1 2022 | $7,746,000 | +2.9% | 26,408 | +15.5% | 0.66% | +7.8% |
Q4 2021 | $7,525,000 | +27.4% | 22,872 | +17.9% | 0.61% | +13.9% |
Q3 2021 | $5,907,000 | -0.5% | 19,403 | -12.3% | 0.54% | -10.0% |
Q2 2021 | $5,934,000 | +16.6% | 22,112 | -2.2% | 0.60% | +11.6% |
Q1 2021 | $5,088,000 | -13.5% | 22,606 | -14.6% | 0.54% | -10.2% |
Q4 2020 | $5,880,000 | +5.5% | 26,467 | +2.3% | 0.60% | -4.8% |
Q3 2020 | $5,572,000 | -1.5% | 25,877 | -19.1% | 0.63% | -5.7% |
Q2 2020 | $5,657,000 | +24.9% | 31,990 | -2.2% | 0.66% | +6.1% |
Q1 2020 | $4,529,000 | -24.1% | 32,725 | -15.8% | 0.63% | -7.7% |
Q4 2019 | $5,964,000 | +16.0% | 38,858 | +9.2% | 0.68% | +2.1% |
Q3 2019 | $5,141,000 | -1.0% | 35,596 | -2.1% | 0.66% | -5.1% |
Q2 2019 | $5,193,000 | +4.4% | 36,344 | -3.6% | 0.70% | +1.2% |
Q1 2019 | $4,974,000 | +10.2% | 37,686 | -13.9% | 0.69% | +0.1% |
Q4 2018 | $4,512,000 | +53.2% | 43,756 | +61.4% | 0.69% | +71.7% |
Q3 2018 | $2,946,000 | +5.8% | 27,118 | -3.9% | 0.40% | +2.0% |
Q2 2018 | $2,784,000 | -0.4% | 28,219 | -1.1% | 0.40% | -1.5% |
Q1 2018 | $2,794,000 | +24.0% | 28,547 | +17.5% | 0.40% | +25.7% |
Q4 2017 | $2,254,000 | +2.1% | 24,286 | -5.6% | 0.32% | -0.6% |
Q3 2017 | $2,207,000 | -20.5% | 25,734 | -21.8% | 0.32% | -21.9% |
Q2 2017 | $2,775,000 | -1.0% | 32,887 | +0.4% | 0.41% | -4.4% |
Q1 2017 | $2,802,000 | -16.8% | 32,764 | -24.3% | 0.43% | -21.0% |
Q4 2016 | $3,367,000 | -4.6% | 43,256 | -4.0% | 0.54% | -4.7% |
Q3 2016 | $3,531,000 | -24.3% | 45,054 | -2.5% | 0.57% | -26.9% |
Q2 2016 | $4,667,000 | – | 46,210 | – | 0.78% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |